JP2019509329A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509329A5
JP2019509329A5 JP2018556016A JP2018556016A JP2019509329A5 JP 2019509329 A5 JP2019509329 A5 JP 2019509329A5 JP 2018556016 A JP2018556016 A JP 2018556016A JP 2018556016 A JP2018556016 A JP 2018556016A JP 2019509329 A5 JP2019509329 A5 JP 2019509329A5
Authority
JP
Japan
Prior art keywords
administered
oncos
adenovirus
malignant mesothelioma
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018556016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509329A (ja
JP6974350B2 (ja
Filing date
Publication date
Priority claimed from FI20165026A external-priority patent/FI127460B/en
Application filed filed Critical
Publication of JP2019509329A publication Critical patent/JP2019509329A/ja
Publication of JP2019509329A5 publication Critical patent/JP2019509329A5/ja
Priority to JP2021180012A priority Critical patent/JP2022023978A/ja
Application granted granted Critical
Publication of JP6974350B2 publication Critical patent/JP6974350B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018556016A 2016-01-15 2017-01-11 がんを治療するためのアデノウイルス及び化学療法剤の組合せ Expired - Fee Related JP6974350B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021180012A JP2022023978A (ja) 2016-01-15 2021-11-04 がんを治療するためのアデノウイルス及び化学療法剤の組合せ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20165026 2016-01-15
FI20165026A FI127460B (en) 2016-01-15 2016-01-15 Combining adenovirus and chemotherapeutic agents for treating cancer
PCT/FI2017/050010 WO2017121925A1 (en) 2016-01-15 2017-01-11 Combining adenovirus and chemotherapeutic agents for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021180012A Division JP2022023978A (ja) 2016-01-15 2021-11-04 がんを治療するためのアデノウイルス及び化学療法剤の組合せ

Publications (3)

Publication Number Publication Date
JP2019509329A JP2019509329A (ja) 2019-04-04
JP2019509329A5 true JP2019509329A5 (enExample) 2020-02-20
JP6974350B2 JP6974350B2 (ja) 2021-12-01

Family

ID=57909646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018556016A Expired - Fee Related JP6974350B2 (ja) 2016-01-15 2017-01-11 がんを治療するためのアデノウイルス及び化学療法剤の組合せ
JP2021180012A Pending JP2022023978A (ja) 2016-01-15 2021-11-04 がんを治療するためのアデノウイルス及び化学療法剤の組合せ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021180012A Pending JP2022023978A (ja) 2016-01-15 2021-11-04 がんを治療するためのアデノウイルス及び化学療法剤の組合せ

Country Status (8)

Country Link
US (1) US20190000898A1 (enExample)
EP (2) EP3985120A1 (enExample)
JP (2) JP6974350B2 (enExample)
CN (2) CN108495934B (enExample)
ES (1) ES2904611T3 (enExample)
FI (1) FI127460B (enExample)
PL (1) PL3402889T3 (enExample)
WO (1) WO2017121925A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
CA3074901A1 (en) 2017-09-11 2019-03-14 Imba - Institut Fur Molekulare Biotechnologie Gmbh Tumor organoid model

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006633A1 (en) 1998-05-15 2001-07-05 David Kirn Adenovirus-chemotherapeutic combination for treating cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
EP2197917A1 (en) * 2007-09-28 2010-06-23 Universitätsspital Basel Immunoliposomes for treatment of cancer
WO2009044158A2 (en) * 2007-10-03 2009-04-09 Cancer Research Technology Limited Inhibitors and uses
CN101411710B (zh) * 2008-11-25 2011-06-15 江苏奥赛康药业有限公司 培美曲塞二钠冻干粉针剂及其制备方法
ES2612889T3 (es) 2008-12-22 2017-05-19 Targovax Oy Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos
CA2865468C (en) * 2011-03-11 2021-05-04 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
EP2806883B1 (en) * 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
SG10201913795TA (en) * 2012-02-02 2020-03-30 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens
DK2908865T3 (en) * 2012-10-17 2019-01-28 Vascular Biogenics Ltd ADENOVIRUS THAT EXPRESSES A PHAS-CHIMARY AND ITS APPLICATION IN CANCER TREATMENT METHODS

Similar Documents

Publication Publication Date Title
ES2964764T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
JP2019206593A5 (enExample)
JP2020509024A5 (enExample)
JP2019536805A5 (enExample)
JP2012506448A5 (enExample)
JP2020523356A5 (enExample)
JP2014148535A5 (enExample)
JP2014513089A5 (enExample)
JP2014040437A5 (enExample)
NZ708506A (en) Methods of treating bladder cancer
JP2020523354A5 (enExample)
JP2015502926A5 (enExample)
HRP20171216T1 (hr) Pripravak koji sadrži aflibercept, folinsku kiselinu, 5-fluorouracil (5-fu) i irinotekan (folfiri)
JP2017506624A5 (enExample)
JP2016510326A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2020523359A5 (enExample)
Gedlicka et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
JP2008514577A5 (enExample)
JP2017514854A5 (enExample)
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
AR079174A1 (es) Composiciones para comprimidos desintegrables oralmente de ondansetron para prevenir nauseas y vomitos
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
JP2019509329A5 (enExample)